Responses
Clinical and epidemiological research
Extended report
Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs
Compose a Response to This Article
Other responses
No responses have been published for this article.